Shields David E, Aclan Jennifer, Szatkowski Aaron
Elan Pharmaceuticals, Inc., South San Francisco, California.
Int J Pharm Compd. 2008 Nov-Dec;12(6):553-7.
The chemical stability of an intrathecally administered analgesic combination may influence the frequency of pump refills necessary to maintain safe and effective analgesia. Previous work has shown that the stability of ziconotide at body temperature is reduced substantially by the presence of morphine sulfate 35 mg/mL. The current study was performed to evaluate the chemical stability of admixtures combining ziconotide with lower concentrations of morphine sulfate during simulated intrathecal infusion under laboratory conditions at 37 deg C. Admixtures containing ziconotide 25 mcg/mL and morphine sulfate 10 mg/mL or 20 mg/mL were stored in implantable intrathecal pumps at 37 deg C and in control vials at 37 deg C or 5 deg C. Samples were obtained over 60 days (admixture containing morphine sulfate 10 mg/mL) or 28 days (admixture containing morphine sulfate 20 mg/mL) and drug concentrations were assessed by high-performance liquid chromatography. Estimates of the time intervals that each admixture retained > or= 90% and > or = 80% of the initial concentrations of both drugs (i.e., the 90% and 80% stabilites) were based on 95% confidence bounds obtained via linear regression. Morphine sulfate 10 mg/mL, the mean ziconotide concentration declined to 81.4% of the initial concentration in 60 days, and 90% and 80% stabilites were maintained for 34 days and 65 days, respctively. In the admixture containing morphine sulfate 20 mg/mL, the mean ziconotide concentration declined to 85.3% of the initial concentration in 28 days, and 90% and 80% stabilities were maintained for 19 days and 37 days, respectively. Decreasing the concentration of morphine in an admixture containing ziconotide improves the stablity of ziconotide.
鞘内注射镇痛合剂的化学稳定性可能会影响为维持安全有效的镇痛效果而进行泵补充的频率。先前的研究表明,35mg/mL的硫酸吗啡会使齐考诺肽在体温下的稳定性大幅降低。本研究旨在评估在37℃实验室条件下模拟鞘内输注期间,齐考诺肽与较低浓度硫酸吗啡混合后的化学稳定性。含有25mcg/mL齐考诺肽和10mg/mL或20mg/mL硫酸吗啡的合剂分别储存在37℃的植入式鞘内泵以及37℃或5℃的对照瓶中。在60天(含10mg/mL硫酸吗啡的合剂)或28天(含20mg/mL硫酸吗啡的合剂)内采集样本,并通过高效液相色谱法评估药物浓度。每种合剂保持两种药物初始浓度≥90%和≥80%的时间间隔估计值(即90%和80%稳定性)基于通过线性回归获得的95%置信区间。对于含10mg/mL硫酸吗啡的合剂,60天内齐考诺肽平均浓度降至初始浓度的81.4%,90%和80%稳定性分别维持34天和65天。对于含20mg/mL硫酸吗啡的合剂,28天内齐考诺肽平均浓度降至初始浓度的85.3%,90%和80%稳定性分别维持19天和37天。在含齐考诺肽的合剂中降低吗啡浓度可提高齐考诺肽的稳定性。